CR11476A - Granulacion en humedo utilizando un agente secuestrante de agua - Google Patents

Granulacion en humedo utilizando un agente secuestrante de agua

Info

Publication number
CR11476A
CR11476A CR11476A CR11476A CR11476A CR 11476 A CR11476 A CR 11476A CR 11476 A CR11476 A CR 11476A CR 11476 A CR11476 A CR 11476A CR 11476 A CR11476 A CR 11476A
Authority
CR
Costa Rica
Prior art keywords
granulation
wet
sequencing agent
water
water sequencing
Prior art date
Application number
CR11476A
Other languages
English (en)
Inventor
Sun Thomas
Lo Ray
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40623940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11476(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of CR11476A publication Critical patent/CR11476A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen tabletas que comprenden formulaciones estables hidroliticamente de sal disodica de (6-(5-fluor-2-(2,4-5trimetoxifenilamino) pirimidin-4-ilamino)-2,2-dimetil-3-oxo-2h-pirido.
CR11476A 2007-11-07 2010-06-03 Granulacion en humedo utilizando un agente secuestrante de agua CR11476A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98623707P 2007-11-07 2007-11-07

Publications (1)

Publication Number Publication Date
CR11476A true CR11476A (es) 2010-08-27

Family

ID=40623940

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11476A CR11476A (es) 2007-11-07 2010-06-03 Granulacion en humedo utilizando un agente secuestrante de agua

Country Status (34)

Country Link
US (3) US8263122B2 (es)
EP (1) EP2217241B1 (es)
JP (1) JP5567487B2 (es)
KR (2) KR101663838B1 (es)
CN (1) CN101998857A (es)
AU (1) AU2008323938B2 (es)
BR (1) BRPI0820389A2 (es)
CA (1) CA2704474C (es)
CO (1) CO6280491A2 (es)
CR (1) CR11476A (es)
CU (1) CU23915B1 (es)
CY (1) CY1122163T1 (es)
DK (1) DK2217241T3 (es)
DO (1) DOP2010000136A (es)
EA (1) EA020210B1 (es)
EC (1) ECSP10010233A (es)
ES (1) ES2672519T3 (es)
HN (1) HN2010000930A (es)
HR (1) HRP20181174T1 (es)
HU (1) HUE039193T2 (es)
IL (1) IL205204A (es)
LT (1) LT2217241T (es)
MX (1) MX2010004733A (es)
MY (1) MY169761A (es)
NI (1) NI201000078A (es)
NZ (1) NZ585913A (es)
PL (1) PL2217241T3 (es)
PT (1) PT2217241T (es)
RS (1) RS57525B1 (es)
SG (1) SG185961A1 (es)
SI (1) SI2217241T1 (es)
TR (1) TR201807879T4 (es)
UA (1) UA102825C2 (es)
WO (1) WO2009061909A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080223392A1 (en) * 2007-03-14 2008-09-18 L'oreal Process for relaxing or straightening hair
GB0814688D0 (en) 2008-08-12 2008-09-17 Knauf Insulation Thermal insulation product
WO2011027333A1 (en) * 2009-09-07 2011-03-10 Douglas Robert Cleverly Granulated anthelmintic preparations and delivery systems
AU2011218805A1 (en) * 2010-02-24 2012-08-30 Auspex Pharmaceuticals, Inc. Trimethoxyphenyl inhibitors of tyrosine kinase
SMT201900071T1 (it) 2011-07-28 2019-02-28 Rigel Pharmaceuticals Inc Nuove formulazioni di (trimetossifenilammino)pirimidinile
US20180296579A1 (en) 2015-04-24 2018-10-18 Rigel Pharmaceuticals, Inc. Methods of treating ibrutinib-resistant disease
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
IT201800007440A1 (it) 2018-07-23 2020-01-23 Composizioni comprendenti un estratto di mirtillo rosso e fosfolipidi
JP2023518356A (ja) 2020-03-12 2023-05-01 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｃｏｖｉｄ－１９関連状態の治療のための方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904477A (en) * 1987-07-08 1990-02-27 American Home Products Corporation Spray dried ibuprofen compositions
US5763172A (en) * 1992-01-21 1998-06-09 Board Of Regents, The University Of Texas System Method of phosphate ester hydrolysis
US5358652A (en) * 1992-10-26 1994-10-25 Ethyl Petroleum Additives, Limited Inhibiting hydrolytic degradation of hydrolyzable oleaginous fluids
AU754965B2 (en) * 1997-12-31 2002-11-28 University Of Kansas, The Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
US6238677B1 (en) * 1998-08-18 2001-05-29 The United States Of America As Represented By The Secretary Of Agriculture Starch microcapsules for delivery of active agents
US6716453B1 (en) * 1999-05-20 2004-04-06 Verion, Inc. Method for increasing the active loading of compressible composition forms
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20060018972A1 (en) * 2002-11-26 2006-01-26 Upm Pharmaceuticals, Inc. Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
ITMI20040498A1 (it) * 2004-03-16 2004-06-16 Solvay Solexis Spa Composizioni granulari
US7449458B2 (en) * 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8227455B2 (en) * 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
US20110052685A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
US20110237609A1 (en) * 2010-03-29 2011-09-29 Chelsea Therapeutics, Inc. Antifolate compositions

Also Published As

Publication number Publication date
MY169761A (en) 2019-05-15
JP5567487B2 (ja) 2014-08-06
KR20150129067A (ko) 2015-11-18
CA2704474A1 (en) 2009-05-14
DOP2010000136A (es) 2010-09-30
HN2010000930A (es) 2012-11-12
SG185961A1 (en) 2012-12-28
BRPI0820389A2 (pt) 2015-05-19
KR101663838B1 (ko) 2016-10-07
CU20100089A7 (es) 2011-10-05
AU2008323938B2 (en) 2014-04-10
US20130189359A1 (en) 2013-07-25
US8372415B2 (en) 2013-02-12
HUE039193T2 (hu) 2018-12-28
WO2009061909A2 (en) 2009-05-14
KR20100088622A (ko) 2010-08-09
PT2217241T (pt) 2018-06-11
US8652492B2 (en) 2014-02-18
CA2704474C (en) 2016-04-26
US20090123539A1 (en) 2009-05-14
RS57525B1 (sr) 2018-10-31
EP2217241A2 (en) 2010-08-18
CY1122163T1 (el) 2020-07-31
AU2008323938A1 (en) 2009-05-14
CU23915B1 (es) 2013-07-31
ECSP10010233A (es) 2010-07-30
DK2217241T3 (en) 2018-08-06
IL205204A (en) 2015-07-30
CO6280491A2 (es) 2011-05-20
EA201070570A1 (ru) 2010-10-29
EA020210B1 (ru) 2014-09-30
US20120288543A1 (en) 2012-11-15
CN101998857A (zh) 2011-03-30
WO2009061909A3 (en) 2009-11-05
IL205204A0 (en) 2010-12-30
MX2010004733A (es) 2010-06-25
NZ585913A (en) 2012-06-29
HRP20181174T1 (hr) 2018-09-21
LT2217241T (lt) 2018-09-10
TR201807879T4 (tr) 2018-06-21
JP2011503010A (ja) 2011-01-27
US8263122B2 (en) 2012-09-11
UA102825C2 (ru) 2013-08-27
SI2217241T1 (sl) 2018-10-30
ES2672519T3 (es) 2018-06-14
EP2217241B1 (en) 2018-04-25
NI201000078A (es) 2011-05-16
PL2217241T3 (pl) 2018-11-30

Similar Documents

Publication Publication Date Title
HN2010000930A (es) Granulacion en humedo que utiliza un agente secuestrante de agua
ES2544967T3 (es) Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas
AR059194A1 (es) Formas de dosificacion resistentes a la manipulacion
ATE539782T1 (de) Lösungen enthaltend bikarbonat fur dialysetherapie
AR052238A1 (es) Formulacion de tabletas estables
HN2008001103A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina
DE60334678D1 (de) Antikörper enthaltende pharmazeutische lösungen
CR9262A (es) Formulaciones en tableta de cci-1179 oralmente biodisponibles
BRPI0407430A (pt) Sal do ácido benzenossulfÈnico com clopidogrel, processos para preparação do mesmo, e para purificação de clopidogrel, uso de um sal, formulação farmacêutica, partìculas de substância ativa, uso de partìculas de substância ativa, e, processo para preparação de partìculas de substância ativa
ATE388703T1 (de) Pharmazeutische formulierung des telmisartan natriumsalzes
UY27418A1 (es) Formulaciones en combinación de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilización
NI200900071A (es) Compuestos de pirozolina y su uso y composiciones farmacéuticas. pc 33496a.
HN2003000185A (es) Difenilazetidinonas sustituidas en grupo acido, procedimiemto para su preparacion, medicamentos que comprenden estso compuestos y su uso.
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
DE602004018142D1 (de) Pharmazeutische formulierung mit levothyroxin-natrium
BRPI0410044A (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
DK1638418T3 (da) Aminosyretilsætning til et sundt mikrobiota-økosystem
GT200800297A (es) Formulaciones galenicas de alisquireno e hidroclorotiazida
GT200500358A (es) Compuestos organicos
EP1900368A4 (en) TABLET WITH A SPIRIT OF SOLUBLE ACTIVE SUBSTANCE
PA8606601A1 (es) Sistemas emulsionantes que contienen derivados de azetidina
EP2124963A4 (en) COMPOSITION WITH A BISPHOSPHONIC ACID IN COMBINATION WITH VITAMIN D
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
IS7290A (is) Lyfjasamsetningar sem innihalda risperidone
ITRM20040516A1 (it) Calzatura di stimolazione per lo sviluppo corretto delle arcate plantari.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)